Denosumab rozšiřuje možnosti farmakoterapie kostního postižení pacientů s karcinomem prostaty

• Title in English: DENOSUMAB EXTENDS THE POOL OF PHARMACOTHERAPY OPTIONS FOR THE MANAGEMENT OF SKELETAL INVOLVEMENT IN PATIENTS WITH PROSTATE CANCER
• Authors: PACÍK Dalibor
• Year of publication: 2012
• Type: Article in Periodical
• Magazine / Source: Urologické listy
• MU Faculty or unit: Faculty of Medicine
• Field: Other medical specializations
• Keywords: prostate cancer; denosumab; SRE; zoledronic acid; bone metastases; CTIBL

Attached files

• Denosumab_rozsiruje_moznosti_farmakoterapie_kostniho_postizeni_pacientu_s_karcinomem_prostaty_UL-2012-2-11.pdf

• Description: A high percentage of prostate cancer patients are at risk of skeletal involvement. Osteoporosis secondary to hormonal ablative therapy and skeletal adverse events as a result of metastatic bone involvement have a negative impact on the patients’ quality of life and their prognosis. Prevalence and delay of SRE must therefore be foregrounded. This article summarizes available evidence about fully-human monoclonal antibody denosumab. This agens has a novel mechanism of action, and thus extends the pool of medicaments influencing bone metabolism. This article is based on data from trials directly comparing denosumab and zoledronic acid, which represents current standard in the treatment of patients with prostate cancer with bone involvement.